Pfizer discontinues two Phase III compounds
This article was originally published in Scrip
Executive Summary
Pfizer has discontinued development of two investigational compounds in Phase III development for fibromyalgia (esreboxetine) and generalised anxiety disorder (PD 332,334) as neither of the drugs would represent an improvement over current therapies, it said.